Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C
This article was originally published in The Pink Sheet Daily
Executive Summary
Question now is whether the long-acting version of interferon will be able to make a “me-better” case based on dosing and quality of life benefits.
You may also be interested in...
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.
Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say
The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product